Early Clinical Response Predicts Treatment Persistence in Advanced Therapy–naive Atopic Dermatitis
DOI:
https://doi.org/10.2340/actadv.v106.adv-2026-0778Keywords:
atopic dermatitis, biological products, Janus kinase inhibitors, medication adherence, medication persistence, pharmacoepidemiologyAbstract
Treatment persistence is a key real-world outcome integrating effectiveness and tolerability in moderate-to-severe atopic dermatitis (AD). We conducted a retrospective multicentre cohort study in 146 advanced therapy–naïve patients with moderate-to-severe AD initiating dupilumab, anti IL-13 agents or JAK inhibitors (JAKi) between April 2022 and April 2025 at 2 secondary-care hospitals in Madrid, Spain. Overall persistence rates were 82.9%, 69.8%, 59.5% and 54.5% at 6, 12, 18 and 24 months, respectively, with significant differences across therapeutic groups (log-rank p=0.025). In multivariable Cox regression, JAKi were associated with higher discontinuation risk compared with dupilumab (HR 1.79; 95% CI 1.05–3.05; p=0.034) and male sex was independently associated with increased discontinuation risk (HR 2.20; 95% CI 1.27–3.81; p=0.005). Early clinical response at week 16 was the strongest predictor: each 1% increase in EASI improvement was associated with a 3% reduction in discontinuation risk (HR 0.97; 95% CI 0.96 0.98; p<0.001). A parallel gradient was observed using patient-reported pruritus (NRS), confirming the predictive value of both objective and patient reported measures. Baseline biomarkers were not independently associated with persistence. These findings support week 16 as a clinically meaningful decision point for response-guided treatment evaluation in routine practice.
Downloads
References
Wollenberg A, Christen-Zäch S, Taieb A, Paul C, Thyssen JP, de Bruin-Weller M, et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol 2020; 34: 2717–2744. DOI: https://doi.org/10.1111/jdv.16892
Davis DMR, Drucker AM, Alikhan A, Bercovitch L, Cohen DE, Darr JM, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol 2024; 90: e43–e56. DOI: https://doi.org/10.1016/j.jaad.2023.08.102
Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016; 375: 2335–2348. DOI: https://doi.org/10.1056/NEJMoa1610020
Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2). Lancet 2021; 397: 2151–2168. DOI: https://doi.org/10.1016/S0140-6736(21)00588-2
Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, Lacour JP, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol 2021; 184: 437–449. DOI: https://doi.org/10.1111/bjd.19574
Silverberg JI, Guttman-Yassky E, Thaçi D, Irvine AD, Stein Gold L, Blauvelt A, et al. Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med 2023; 388: 1080–1091. DOI: https://doi.org/10.1056/NEJMoa2206714
Kim RW, Lam M, Abuabara K, Simpson EL, Drucker AM. Targeted systemic therapies for adults with atopic dermatitis: selecting from biologics and JAK inhibitors. Am J Clin Dermatol 2024; 25: 179–193. DOI: https://doi.org/10.1007/s40257-023-00837-w
van den Reek JMPA, Kievit W, Gniadecki R, Goeman JJ, Zweegers J, van de Kerkhof PCM, et al. Drug survival studies in dermatology: principles, purposes, and pitfalls. J Invest Dermatol 2015; 135: 1–5. DOI: https://doi.org/10.1038/jid.2015.171
Ariëns LFM, van der Schaft J, Bakker DS, Balak D, Romeijn MLE, Kouwenhoven T, et al. Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: first clinical and biomarker results from the BioDay registry. Allergy 2020; 75: 116–126. DOI: https://doi.org/10.1111/all.14080
De Bruin-Weller M, Biedermann T, Bissonnette R, Deleuran M, Foley P, Girolomoni G, et al. Treat-to-target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies. Acta Derm Venereol 2021; 101: adv00402. DOI: https://doi.org/10.2340/00015555-3751
Jonsson PO, Tayefi M, Svedbom A, Bradley M, Johansson EK. Drug survival and predictors of systemic treatment outcome in atopic dermatitis: data from a nationwide Swedish cohort. Acta Derm Venereol 2025; 105: adv43464. DOI: https://doi.org/10.2340/actadv.v105.43464
Schlosser AR, Nijman L, Schappin R, Nijsten TEC, Hijnen D. Long-term outcomes of new systemic agents in atopic dermatitis: drug survival analyses and treatment patterns in daily practice. Acta Derm Venereol 2025; 105: adv41504. DOI: https://doi.org/10.2340/actadv.v105.41504
Thyssen JP, Vestergaard C, Deleuran MS, et al. European Task Force on Atopic Dermatitis (ETFAD): treatment targets and treatable traits in atopic dermatitis. J Eur Acad Dermatol Venereol 2022; 36: 1929–1936.
Spekhorst LS, de Graaf M, Zuithoff NPA, van den Reek JMPA, Kamsteeg M, Boesjes CM, et al. Dupilumab drug survival and associated predictors in patients with moderate to severe atopic dermatitis: long-term results from the daily practice BioDay registry. JAMA Dermatol 2022; 158: 1048–1056. DOI: https://doi.org/10.1001/jamadermatol.2022.3014
Leshem YA, Hajar T, Hanifin JM, Simpson EL. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol 2015; 172: 1353–1357. DOI: https://doi.org/10.1111/bjd.13662
Schmitt J, Spuls PI, Thomas KS, Simpson E, Furue M, Deckert S, et al. The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. J Allergy Clin Immunol 2014; 134: 800–807. DOI: https://doi.org/10.1016/j.jaci.2014.07.043
Hendrix N, Marcum ZA, Veenstra DL. Approaches to measuring medication persistence and their implications for benefit-risk assessments. Pharmacoepidemiol Drug Saf 2020; 29: 675–683. DOI: https://doi.org/10.1002/pds.5021
de la Cueva Dobao P, Notario J, Ferrándiz C, et al. Persistence of biologic therapy in moderate to severe plaque psoriasis: expert recommendations. J Eur Acad Dermatol Venereol 2019; 33: 1214–1223. DOI: https://doi.org/10.1111/jdv.15600
van der Gang LF, Boesjes CM, Zuithoff NPA, Haeck I, Bacoş-Cosma O, Loman L, et al. Drug survival in atopic dermatitis: comparison of biologics and JAK inhibitors in the BioDay registry. Allergy 2026; 81: 609–613. DOI: https://doi.org/10.1111/all.70187
Prieto-Merino D, Mulick A, Armstrong C, Hoult H, Fawcett S, Eliasson L, et al. Estimating proportion of days covered (PDC) using real-world online medicine suppliers’ datasets. J Pharm Policy Pract 2021; 14: 113. DOI: https://doi.org/10.1186/s40545-021-00385-w
Tsai SY, Phipatanakul W, Hawryluk EB, et al. Comparative safety of Janus kinase inhibitors and dupilumab in atopic dermatitis. J Allergy Clin Immunol 2024; 154: 1195–1203. DOI: https://doi.org/10.1016/j.jaci.2024.07.019
Drucker AM, Lam M, Prieto-Merino D, Malek R, Ellis AG, Yiu ZZN, et al. Systemic immunomodulatory treatments for atopic dermatitis: living systematic review and network meta-analysis update. JAMA Dermatol 2024; 160: 936–944. DOI: https://doi.org/10.1001/jamadermatol.2024.2192
Weidinger S, Novak N, Bieber T. Serum biomarkers in atopic dermatitis. J Eur Acad Dermatol Venereol 2022; 36: 865–878.
Additional Files
Published
How to Cite
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
